RxDoctor Payments DataLook up a doctor →

Donald Goodin, MD

Hematology & Oncology · Glasgow, KYNPI 1922102391

Payments from drug & device makers

$16,154in general payments, 2019–2025

Across 898 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$1K
  • AstraZeneca$1K
  • Johnson & Johnson$882
  • Daiichi Sankyo Inc.$811
  • Genentech USA, Inc.$771
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$15,89598%
  • Education$2592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$1,382
Merck66$1,135
AstraZeneca(2 entities)58$1,024
Johnson & Johnson52$882
Daiichi Sankyo Inc.42$811
Genentech USA, Inc.47$771
Pfizer44$726
Amgen25$586
Takeda Pharmaceuticals U.S.A., Inc.28$574
Eisai Inc.27$510
Gilead(2 entities)28$467
Sanofi18$446
Incyte Corporation25$434
AbbVie22$390
E.r. Squibb & Sons, L.L.C.28$385
Bristol Myers Squibb19$341
Seagen Inc.15$275
Lilly USA, LLC13$228
GSK12$226
Array Biopharma Inc20$224
EMD Serono, Inc.10$221
Regeneron Healthcare Solutions, Inc.7$220
Bayer14$209
Coherus Oncology, Inc.10$209
AVEO Pharmaceuticals, Inc.13$202
Karyopharm Therapeutics Inc.10$180
Sun Pharmaceutical Industries Inc.8$174
Puma Biotechnology, Inc.10$171
Astellas Pharma US Inc11$170
Blueprint Medicines Corporation6$155
Stemline Therapeutics Inc.8$146
Beigene USA, Inc.8$135
Tersera Therapeutics LLC7$126
Ipsen Biopharmaceuticals, Inc7$115
ADC Therapeutics America, Inc.7$112
Geron Corporation3$108
Taiho Oncology, Inc.5$108
Boehringer Ingelheim5$105
Tempus AI, Inc4$104
Pharmacyclics LLC, An Abbvie Company5$103
Sobi, Inc5$96
Rigel Pharmaceuticals, Inc.5$82
Pharmacosmos Therapeutics Inc.4$73
Genmab U.S., Inc.3$71
Jazz Pharmaceuticals Inc.4$70
Mirati Therapeutics, Inc.4$66
Exelixis Inc.4$57
Pharmaessentia USA Corporation3$55
Morphosys, US Inc.3$53
G1 Therapeutics, Inc.3$50
Sumitomo Pharma America, Inc.3$48
Fennec Pharmaceuticals, Inc.3$44
Springworks Therapeutics, Inc.2$39
Clovis Oncology, Inc.2$33
Teva Pharmaceuticals USA, Inc.2$33
Kyowa Kirin, Inc.2$32
Dova Pharmaceuticals2$30
Alnylam Pharmaceuticals Inc.1$30
Myovant Sciences Inc.2$27
Progenics Pharmaceuticals, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,154 in reported general payments places this provider in the 55th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$145,655
Medicare patients
482
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib37$580,030
RevlimidLenalidomide30$522,799
XtandiEnzalutamide42$510,874
IbrancePalbociclib26$404,694
KisqaliRibociclib Succinate31$346,179
PomalystPomalidomide14$320,592
MekinistTrametinib Dimethyl Sulfoxide13$188,958
Lenalidomide14$180,659
BrukinsaZanubrutinib13$178,785
PromactaEltrombopag Olamine12$156,361
TafinlarDabrafenib Mesylate13$94,340
Abiraterone Acetate17$39,607
EliquisApixaban24$26,173
Ondansetron Hcl202$8,245
Imatinib Mesylate18$5,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Mekinist, Promacta, Tafinlar$1,382$785,83769 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$103$580,03037 claims
Bristol Myers SquibbRevlimid$341$522,79930 claims
Astellas Pharma US IncXtandi$170$510,87442 claims
PfizerIbrance, Eliquis$726$430,86750 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$385$320,59214 claims
Beigene USA, Inc.Brukinsa$135$178,78513 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$33$53441 claims
Lilly USA, LLCOlanzapine$228$14561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →